Olon

Executive Summary

Olon is a global leader in the development and manufacturing of Active Pharmaceutical Ingredients (APIs), serving CDMO and generic markets. Founded in 1971 in Rodano, Italy, the company combines advanced chemical synthesis and microbial biomanufacturing across a global facility network. Its commitment to quality, regulatory expertise, and sustainable practices positions it as a trusted partner for pharmaceutical companies. As a private entity, Olon does not disclose financials, but its long-standing industry presence and diversified capabilities suggest stable operations. The company benefits from the growing demand for outsourced API manufacturing, driven by patent expirations and supply chain diversification. However, lack of public data limits visibility into near-term performance. Overall, Olon represents a well-established player in a resilient sector, with potential for steady growth through capacity expansions and strategic partnerships.

Upcoming Catalysts (preview)

• Q2 2026Expansion of manufacturing capacity in Europe or US70% success
• Q3 2026New long-term CDMO contract with a top-20 pharma50% success
• Q4 2026Acquisition of a complementary API technology platform40% success